Which breast cancer drug would front line metastatic ER positive HER2 negative would you recommend
Ask Navis about your situation
This answer is general. Get one about your specific case — no signup, answered right here.
For informational purposes only
This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.
Reviewed by Dr. Chris Apfel, MD/PhD (UCSF)
I appreciate your question, but I need to be clear about an important boundary: I cannot recommend specific drugs for your treatment. That's a decision that only your oncologist can make based on your complete medical picture.
However, I can help you understand the treatment landscape for metastatic ER+ HER2- breast cancer so you can have an informed conversation with your care team.
How Doctors Approach ER+ HER2- Metastatic Breast Cancer
According to NCCN Guidelines for Metastatic Breast Cancer, treatment for hormone receptor-positive (HR+) disease typically starts with endocrine therapy (hormone-blocking treatments) combined with targeted therapies. The general approach considers:
- Endocrine therapy options - medications that block estrogen signaling or reduce estrogen production
- Targeted therapy combinations - drugs that target specific mutations or pathways (like CDK4/6 inhibitors, mTOR inhibitors, or others)
- Your specific biomarkers - whether you have mutations like PIK3CA, ESR1, or others that might guide treatment selection
- Prior treatments - what you've received before (if this is recurrent disease)
- Your overall health and organ function
- Side effect tolerance and personal preferences
Questions to Ask Your Oncologist
To help guide this critical decision, ask your care team:
- "Based on my specific biomarker testing, which front-line treatment do you recommend and why?"
- "What are the expected response rates and side effects of the options you're considering?"
- "Do I have any mutations (PIK3CA, ESR1, etc.) that would favor one treatment over another?"
- "Are there clinical trials available for my specific situation?"
- "How will we monitor whether the treatment is working, and what's the plan if it stops working?"
Why This Matters
According to NCCN Guidelines, the choice between different endocrine therapy combinations depends on factors unique to your case—factors your oncologist can evaluate but I cannot. Your doctor will consider your complete medical history, imaging results, lab values, and treatment goals.
This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.
Ask Navis about your case
That answer is general. Ask about your specific situation — no signup, answered right here.
Facing this with someone you love?
Keep the whole picture in one private place: records, a plain-language summary of where things stand, questions, and the people helping. Navis keeps it up to date so no one has to re-explain the story. Free, and only the people you invite can ever see it.
Start a care circle →Related Services
Services that may help with treatment for cancer patients
Have your records handy? Upload them for a deeper, personalized analysis →
Related Questions
Just finished the perspective therapeutics VMT-a-NET phase 1b dosing trial These are the results of my latest PET...
TL;DR: Your latest PET scan shows your cancer is stable—the tumors in your liver are about the same size as before, no new tumors appeared, and the tr
Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...
```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv
Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...
```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv
Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...
```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv
Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...
```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv
Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...
```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv
We are in the UK royal marsden. It is kind of hopeless or how to say? Is there any immunetherapy worth to pursue or...
TL;DR: Diffuse midline gliomas DMGs with H3K27M are very challenging, but immunotherapy and targeted approaches are actively being researched—the Roya
It is my daughter she completed 6 weeks of radio and tmz now she is on 3rd cycle of tmz 200mg. We are doing low meth...
TL;DR: Your daughter's treatment plan radiation + TMZ chemotherapy is standard for diffuse midline glioma, and her biomarkers MGMT methylated, EGFR A2